The Society for Immunotherapy of Cancer (SITC) invites all members of the society to provide feedback and comments on the “An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0”
At the end of this 30-day comment period, the Steering Committee for the Cancer Immunotherapy Guidelines for Bladder Cancer will review the comments to determine whether and how to revise the manuscript.
Please note that your name and institution will be posted along with your comments. In addition, all comments received will be published as supplemental information with the manuscript.
Below is an easy three-step process explaining how to submit your comments:
If you have any questions concerning the content of the manuscript or the open comment period, please email email@example.com.
If you have any technical questions or need help posting a comment, please contact Community Manager Martha Jack at firstname.lastname@example.org.
The Cancer Immunotherapy Guidelines initiative began in 2010, when a group of researchers and clinicians united to address the lack of formal guidance on the use of cancer immunotherapy. As a part of this initiative, knowledge gaps were identified in four main areas related to the clinical application of cancer immunotherapy:
The goal of the Melanoma Guidelines Task Force is to publish an evidence-based consensus statement on the use of immunotherapy for the treatment of melanoma. The consensus statement will primarily address the needs of practicing oncologists, although it is also designed to be of use to other clinicians in this area. Because guidelines from other organizations do not address certain unique aspects of immunotherapy, the goal of this document is to provide consensus recommendations that specifically address the use of cancer immunotherapy.
Guidelines for kidney, prostate, bladder and hematologic cancers have been published in the past year. Cancer Immunotherapy Guidelines for lung cancer are currently in development.
The consensus statement will provide information to help clinicians determine when immunotherapy is appropriate for their cancer patients, and how to use and monitor treatment appropriately. Guidelines development follows a systematic process to ensure the recommendations are unbiased, relevant, and facilitate clinical decision-making. Because the field of cancer immunotherapy is rapidly advancing, these guidelines will be evaluated and updated on an ongoing basis.
This consensus statement was developed by a Task Force comprising physicians as well as nurse and patient advocate representatives with expertise in, or experience of, melanoma treatment. The Task Force was led by a Steering Committee. A full list of the Melanoma Guidelines Task Force members can be found here.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com